Loading...
XSHE
000919
Market cap650mUSD
Dec 05, Last price  
7.39CNY
1D
-0.14%
1Q
3.36%
Jan 2017
-45.38%
Name

Jinling Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHE:000919 chart
P/E
113.74
P/S
1.40
EPS
0.06
Div Yield, %
1.35%
Shrs. gr., 5y
3.29%
Rev. gr., 5y
5.30%
Revenues
3.28b
+17.79%
1,235,800,2831,375,734,3131,548,968,8911,788,881,9641,966,705,7662,161,139,2872,257,022,7772,304,934,2202,605,713,7822,771,942,2863,221,375,3853,578,652,7743,191,811,8632,899,079,0222,534,920,5392,503,732,3742,808,754,8762,670,968,0382,785,738,4093,281,450,554
Net income
40m
-59.45%
157,848,357201,827,473307,465,69482,598,435220,957,624192,731,459165,201,943143,556,314155,890,349197,184,453208,109,272180,151,292137,126,464241,786,876145,319,43993,657,703120,625,946105,281,85499,652,60140,409,795
CFO
154m
-2.98%
109,293,829138,503,706118,063,748305,263,648188,410,396177,809,117172,822,179232,116,926271,208,292299,891,714212,449,64196,149,992443,109,707433,825,968465,847,095311,464,432292,026,282260,590,694158,923,988154,190,609
Dividend
May 31, 20240.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; and lentinan injection for treatment of malignant tumors. It also provides medical health care services. Jinling Pharmaceutical Company Limited is based in Nanjing, China.
IPO date
Nov 18, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT